In California, !%Affymetrix Inc.%! of Santa Clara has signed a definitive agreement to acquire eBioscience Inc. of San Diego for $330 million in cash, subject to certain customary adjustments. The transaction was expected to close late in fourth-quarter 2011. “With eBioscience, Affymetrix will significantly expand its addressable markets by adding an industry-leading portfolio of cell-based and immunoassays,” said Dr. Frank Witney, president and CEO of Affymetrix. “These new products are a critical part of our customers’ work flow in our key target markets of translational medicine, oncology and immunology.” The company expects to maintain eBioscience’s management team and operations in San Diego.